Liminatus Pharma【LIMN】銘柄情報

Liminatus Pharma Inc (LIMN) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

0.125

( -8.09% )

買値

0.125

売値

0.1275

出来高

2,551,225

0.1233 日の範囲 0.1406

0.1216 52 週間の範囲 33.66

時価総額

5.61M

前日終値

0.136

始値

0.137

時刻

1000

0.125

(formt)

最終取引時間

財務取引量

US$ 335,397

VWAP

0.131465

平均取引量 (3 か月)

US$ 10,129,710

発行済株式数

44,877,633

配当利回り

PER

-0.37

1 株当たり利益 (EPS)

-0.39

歳入

純利益

-11M

Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-sm... Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California. 詳細を表示

セクター

業界

ウェブサイト

liminatuspharma.com

本社

Cerritos, United States

設立

2026

Liminatus Pharma Inc is listed in the sector of the ナスダック市場 with ticker LIMN. The last closing price for Liminatus Pharma was US$0.14. Over the last year, Liminatus Pharma shares have traded in a share price range of US$ 0.1216 to US$ 33.66.

Liminatus Pharma currently has 44,877,633 shares in issue. The market capitalisation of Liminatus Pharma is US$5.61 million. Liminatus Pharma has a price to earnings ratio (PE ratio) of -0.37.

Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds

FULLERTON, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or...

Liminatus Pharma Announces Nasdaq Delisting Notification

FULLERTON, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the...

Liminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy Pipeline

FULLERTON, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (“Liminatus” or the “Company”...

Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody

CERRITOS, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Liminatus today announced plans to initiate a Phase 1...

Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering

CERRITOS, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN) (“Liminatus” or the “Company”), a pre-clinical stage...

Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation

LA PALMA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a clinical-stage...

Liminatus Pharma Inc. to Launch “American BNB Strategy” Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative

LA PALMA, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a...

Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies

LA PALMA, Calif., July 25, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a...

Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy

LA PALMA, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a...

Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy

LA PALMA, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.0262	-17.328042328	0.1512	0.1548	0.1216	2164359	0.13866603	CS
4	-0.055	-30.5555555556	0.18	0.3583	0.1216	22979561	0.22665083	CS
12	-0.0825	-39.7590361446	0.2075	0.3583	0.1216	10345442	0.21745558	CS
26	-0.734	-85.4481955763	0.859	2.83	0.1216	9082988	0.68934093	CS
52	-12.175	-98.9837398374	12.3	33.66	0.1216	4967472	1.04593931	CS
156	-7.375	-98.3333333333	7.5	33.66	0.1216	4510425	1.15524291	CS
260	-7.375	-98.3333333333	7.5	33.66	0.1216	4510425	1.15524291	CS